How it went
Did it last?
- 3 of 8 said the benefit wore off (including the 2 who relapsed).
- No one said they needed to keep it up to stay well.
Read from what people wrote. A story that ends without a follow-up counts as lasting, so treat these as minimums.
| Outcome described | Accounts | Share |
|---|---|---|
| Full recovery | 3 | 38% |
| Near-full | 1 | 12% |
| Substantial | 0 | 0% |
| Partial | 2 | 25% |
| Relapsed | 2 | 25% |
| No benefit | 0 | 0% |
Only 8 accounts. Treat these percentages as anecdotes, not rates.
By how ill people were
| Severity at worst | How it went | n | Recovered |
|---|---|---|---|
| Severe | 6 | 67% |
2 accounts don’t say how ill the person was.
Who published these accounts
Right-hand number: share describing a full or near-full recovery. Pages that sell something, and advocacy sites, tend to publish only the successes.
All 8 accounts
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Monoclonal antibodies article comments
Credits monoclonal antibody. An unnamed patient was ill 4.5y with severe long COVID, improved, then relapsed. Pemgarda gives 8-10 week remission per dose.
-
Three Long-term Long COVID Patients, Three Rapid Recoveries
Pemivibart (Pemgarda), a monoclonal antibody infusion whose effect the article says typically lasts about a couple of months, was given to three long-term long COVID patients. A 70-year-old woman, sick for nearly a year, had her brain fog, breathlessness and…
-
No easy home runs: early Long COVID Paxlovid and monoclonal trials
Amy Engebretson took part in Yale's PaxLC trial of Paxlovid and has continued taking ritonavir, one of Paxlovid's components, because she says it "improved my symptoms quite a bit"; the article gives no specific dose or treatment duration for her. It does…
-
Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 3)
The third patient, who had type II diabetes and was overweight, was severely ill with long COVID for about five months. After receiving the casirivimab and imdevimab cocktail the post reports his symptoms disappeared within a week. He was reportedly…
-
Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 2)
This patient fell ill with severe long COVID in early 2021, with profound cognitive difficulty and extreme exercise intolerance, and gained only mild relief from vaccination. More than six months later, after testing positive for COVID again, she received…
-
Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 1)
This patient developed severe long COVID after a confirmed infection, unable to climb stairs or walk without severe fatigue and with neurological and cardiac symptoms, gaining only mild relief from vaccination. About a year after infection she received the…
-
The Temporary Recovery Stories (Judith)
Commenter Judith described multiple remissions and relapses since childhood, including a Rituximab course that caused complications. She now manages with AHCC, magnesium, Plaquenil and colchicine, and describes the illness as progressive, each relapse…